MDI

Goodbye Semglee

A long-acting insulin that almost everyone (in the Australian T1 diabetes world anyway) knows of is “Lantus”, even though it was replaced by the identical Optisulin 2 years ago. It took a while to be phased out. A few months prior (back in October 2019) I reported the arrival of “Semglee”. This is marketed by …

Goodbye Semglee Read More »

ATTD’2021: hanging on to the fire-hose

ATTD 2021 (the 14th conference on Advanced Technologies & Treatments for Diabetes) is currently in progress. This is one of the international conferences where some of the latest developments in diabetes management are presented. We see information about new products, the results of research studies, etc. I’m honoured to be a delegate to this year’s …

ATTD’2021: hanging on to the fire-hose Read More »

Lantus is being replaced

Lantus is a long-acting basal insulin which has been around since 2000. That’s about to change, but don’t panic. Essentially it’s just a name change. History Lantus is a U100 form of insulin glargine, made by Sanofi. Its patent protection eventually ran out, so new versions started appearing from other companies. Lilly (who also make Humalog) …

Lantus is being replaced Read More »

Another insulin – October 2019

In the October update to the Australian PBS (Pharmaceutical Benefits Scheme), another insulin arrived today. Well, sort of. The addition is Semglee, which is a “biosimilar equivalent” to Lantus. Like Lantus it’s insulin glargine. Lantus is one of the commonly-used long-acting (or “basal”) insulin used for daily injections. It’s been around for years (I used …

Another insulin – October 2019 Read More »